We are global leaders in cell engineering, using our unique and innovative gene editing and gene modulation platform to build disease models that are then deployed through a wide range of unique tools and services used by our customers to provide valuable insights and applications in areas as varied as research, drug discovery, molecular diagnostics, and biomanufacturing.
Our business model is driven by asset leverage. When a customer approaches Horizon to develop a disease model (cell line or in vivo), we will make it to their specifications. In almost all cases, however, they remain the property of Horizon, becoming a part of our catalogue and allowing us to deploy them however we choose in the future. This includes licensing them to the broader academic and drug development markets for additional revenue.
These same cell lines, with only a change in format, are also the source for Horizon’s molecular reference standards, and the expertise used to generate them can be applied to engineer specialist cells that can be used as highly efficient manufacturing engines for biopharmaceuticals. Further, this catalogue is the foundation for our high-value contract research and molecular and genetic screening services. Finally, our extensive catalogue, specialist contract research services, and deep in-house gene editing and gene modulation expertise provide the foundation for our Research Biotech business.